Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled Phase 1b study evaluates the effects of sevuparin on the symptoms of healthy volunteer participants who have been injected with the bacterial toxin lipopolysaccharide (LPS)

Next Previous
X
Search
Trial Profile

A randomized, placebo-controlled Phase 1b study evaluates the effects of sevuparin on the symptoms of healthy volunteer participants who have been injected with the bacterial toxin lipopolysaccharide (LPS)

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Heparin (Primary) ; Sevuparin (Primary)
  • Indications Endotoxinaemia; Sepsis; Septic shock
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms lipopolysaccharide (LPS) provocation study
  • Sponsors Modus Therapeutics

    • Most Recent Events

    • 05 Oct 2023 According to a Modus Therapeutics media release, final results from this study will be presented as part of the "Best poster presentation" session at the 27th International Symposium on infections in the Critically Ill Patient (ISICIP), October 5-6 in Barcelona, Spain.
    • 21 Feb 2023 Topline data results presented in a Modus Therapeutics media release.
    • 21 Feb 2023 According to a Modus Therapeutics media release, company announced positive top-line data from this trial will be used to design the Modus Phase 2a study of sevuparin in patients with sepsis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top